Dubai: UAE gets first production of herbal medicine, with Globalpharma commissioning new line for anti-inflammatory treatment in Dubai.
The medicine contains a mixture of herbs like myrrh and costus, used for the treatment and prevention of various types of infections ranging from respiratory infections, indigestion, skin infections, headaches and diabetic conditions. The drug has been approved by the Ministry of Health and Prevention (MOHAP).
Globalpharma, a subsidiary of Dubai Investments, produces “MG21” in tandem with Al Fujairah Healing Company. “We believe that this herbal medicine will not only become a popular product with consumers, but will also help strengthen the UAE’s position as a leader in pharmaceuticals in the region,” said Mohammed Saeed Al Raqbani, Managing Director of Dubai Investment Industries.
Al Fujairah Healing Company selected Globalpharma to develop, sell, market, promote and distribute MG21 across the Middle East. Basem AlBarahmeh, Managing Director of the Pharmaceutical Entity, said: “Globalpharma has already signed a distribution agreement with Alphamed, one of the main local suppliers in the country, with the aim of ensuring the availability of MG21 in the majority of pharmacies before the end of this year. “
New herbal production takes place at Globalpharma’s facilities at Dubai Investments Park. There are separate facilities for the manufacture of herbal products and an annual production of approximately 500,000 capsules.